Eterna Therapeutics Inc. (ERNA)
- Previous Close
0.9470 - Open
0.9100 - Bid --
- Ask --
- Day's Range
0.8001 - 0.9300 - 52 Week Range
0.8001 - 2.6300 - Volume
142,646 - Avg. Volume
33,157 - Market Cap (intraday)
42.885M - Beta (5Y Monthly) 7.77
- PE Ratio (TTM)
-- - EPS (TTM)
-4.4300 - Earnings Date Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
eternatx.comRecent News: ERNA
View More
Performance Overview: ERNA
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERNA
View MoreValuation Measures
Market Cap
48.75M
Enterprise Value
95.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
31.71
Price/Book (mrq)
--
Enterprise Value/Revenue
588.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-29.41%
Return on Equity (ttm)
--
Revenue (ttm)
162k
Net Income Avi to Common (ttm)
-23.94M
Diluted EPS (ttm)
-4.4300
Balance Sheet and Cash Flow
Total Cash (mrq)
2.59M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-11.78M
Research Analysis: ERNA
View MoreCompany Insights: ERNA
ERNA does not have Company Insights